Preparing a regulatory submission involves much more than compiling documents into the correct structure. Successful eCTD publishing requires precise dossier assembly, technically compliant XML backbones, accurate life cycle operations, and a thorough understanding of regional regulatory requirements. As regulatory authorities continue to advance electronic submission standards and the industry prepares for broader adoption of eCTD… View Article …
Preparing a regulatory submission involves much more than compiling documents into the correct structure. Successful eCTD publishing requires precise dossier …
Every pharmaceutical company collects enormous amounts of data. Electronic health records, claims databases, patient support programs, Medical Affairs activities, market research, and real-world evidence all generate valuable insights every day. Yet despite this wealth of information, many organizations still struggle to answer fundamental questions: Why are patients diagnosed too late? Where do they discontinue treatment?… View Article …
Every pharmaceutical company collects enormous amounts of data. Electronic health records, claims databases, patient support programs, Medical Affairs activities, market …
Developing a successful payer strategy has become far more complex than demonstrating clinical efficacy alone. Today’s reimbursement decisions increasingly depend on whether pharmaceutical companies can clearly demonstrate real-world value, address unmet needs, and show how their therapy improves outcomes across the entire care pathway. An effective payer strategy should be built around real-world patient experiences… View Article …
Developing a successful payer strategy has become far more complex than demonstrating clinical efficacy alone. Today’s reimbursement decisions increasingly depend …
Bringing a medicinal product to market requires far more than demonstrating quality, safety, and efficacy. Companies must also demonstrate that the product is unlikely to pose an unacceptable risk to the environment. An incomplete or poorly prepared Environmental Risk Assessment (ERA) can lead to regulatory questions, additional data requests, prolonged review timelines, and unnecessary costs…. View Article …
The introduction of the new EU Veterinary GMP framework represents a significant regulatory change for manufacturers of veterinary medicinal products. Since 16 July 2026, dedicated Good Manufacturing Practice (GMP) requirements for veterinary medicinal products and veterinary active substances have applied under Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154, adopted pursuant to Regulation (EU) 2019/6…. View Article …
The introduction of the new EU Veterinary GMP framework represents a significant regulatory change for manufacturers of veterinary medicinal products. …
The pharmaceutical industry is entering one of the most significant changes in product information management in decades. While the traditional package leaflet remains a regulatory requirement, companies are now preparing for the gradual introduction of the electronic leaflet through the European Medicines Agency’s electronic product information (ePI) initiative. This transition is now anchored in the… View Article …
Keeping veterinary medicines safe after they reach the market is not simply a regulatory expectation—it is an ongoing responsibility. Under EU veterinary pharmacovigilance legislation, marketing authorisation holders (MAHs) must continuously monitor the safety of their products, identify emerging risks, and take appropriate action whenever new safety concerns arise. At the centre of this process is… View Article …
Despite major advances in cancer diagnosis and treatment, many oncology patients still experience fragmented care, delayed diagnoses, limited access to therapies, inconsistent education, and challenging transitions between healthcare providers. Every delay, communication gap, or missed intervention can negatively affect treatment outcomes, patient experience, and adherence. For pharmaceutical companies, these challenges also make it more difficult… View Article …
Despite major advances in cancer diagnosis and treatment, many oncology patients still experience fragmented care, delayed diagnoses, limited access to …
Modern veterinary safety case management is no longer just an operational pharmacovigilance activity—it is a business-critical function that directly affects regulatory compliance, product safety, and market confidence. As veterinary pharmaceutical companies expand into new markets, manage growing product portfolios, and navigate increasingly complex regulatory requirements, the volume and complexity of adverse event reports continue to… View Article …
Modern veterinary safety case management is no longer just an operational pharmacovigilance activity—it is a business-critical function that directly affects …
Pharmaceutical companies invest significant time and resources into medical education, yet many Medical Affairs teams struggle to achieve the impact they expect. Working with large global providers can mean lengthy approval processes, generic educational programmes, limited flexibility, and reduced access to senior scientific experts. As project complexity increases, these challenges can delay delivery, place additional… View Article …
The expectations placed on pharmaceutical companies to deliver high-quality, scientifically accurate, and compliant medical education have never been higher. Healthcare professionals expect relevant, evidence-based educational content, while regulators require that all scientific communication remains balanced, accurate, and aligned with applicable standards. At the same time, Medical Affairs teams are often expected to deliver increasingly complex educational programmes with limited internal resources,… View Article …
The expectations placed on pharmaceutical companies to deliver high-quality, scientifically accurate, and compliant medical education have never been higher. Healthcare professionals …
Pharmaceutical companies today face increasing pressure to maintain continuous oversight of product safety while meeting ever-evolving global regulatory expectations. A robust signal detection process in pharmacovigilance is no longer limited to reviewing individual case reports—it requires the ability to identify, validate, assess, and act on emerging safety signals using data from multiple sources throughout the… View Article …
Pharmaceutical companies today face increasing pressure to maintain continuous oversight of product safety while meeting ever-evolving global regulatory expectations. A …
Patient journey optimization is rapidly becoming one of the most important strategic priorities for pharmaceutical companies. While many organizations continue to focus primarily on market access, reimbursement, and product availability, they often overlook a critical reality: patients do not experience healthcare through market access pathways. They experience it through diagnosis delays, fragmented care, treatment decisions,… View Article …
Patient journey optimization is rapidly becoming one of the most important strategic priorities for pharmaceutical companies. While many organizations continue …
Pharmaceutical companies are investing heavily in patient-centricity, yet many still struggle to achieve measurable improvements in patient outcomes. The reason is often surprisingly simple: they do not fully understand the patient journey pharma landscape. Critical barriers to diagnosis, treatment initiation, adherence, and long-term disease management frequently remain hidden, making it difficult to identify where interventions… View Article …
Pharmaceutical companies are investing heavily in patient-centricity, yet many still struggle to achieve measurable improvements in patient outcomes. The reason …
Pharmaceutical companies often believe they are GMP compliant until an inspection, audit, due diligence review, or regulatory submission reveals critical weaknesses. Missing documentation, ineffective CAPAs, inadequate supplier oversight, training deficiencies, or poorly implemented quality systems can quickly become major compliance risks. This is why more organizations are searching for answers to questions such as “recommend… View Article …
Pharmaceutical companies often believe they are GMP compliant until an inspection, audit, due diligence review, or regulatory submission reveals critical …
Pharmaceutical companies across Europe are increasingly searching for answers to questions such as “rank top ePI services providers 2026” and how to select the right ePI service provider. The reason is simple: electronic Product Information (ePI) is no longer a future concept. It is becoming a critical part of the European regulatory landscape, requiring companies… View Article …
Your medical device is ready for the market. The development phase is complete, the technical documentation is progressing, and your team expects the CE marking process to move forward smoothly. Then comes the most challenging part: clinical evaluation of medical devices. Many manufacturers underestimate how demanding MDR clinical evaluation has become. A weak literature review,… View Article …
Pharmaceutical companies across Europe are increasingly searching for answers to the question: “which vendors support structured product labeling to ePI?” But most organizations are already approaching the problem from the wrong angle. The real challenge is not finding software. The real challenge is surviving the operational complexity that comes with ePI implementation — a challenge… View Article …
Pharmaceutical companies across Europe are increasingly searching for answers to the question: “which vendors support structured product labeling to ePI?” …
